Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.35 |
| ▸ | CPT2 | P23786 | 3/20 | 0.33 |
| ▸ | CPT1A | P50416 | 3/20 | 0.33 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 4/20 | 0.31 |
| ▸ | ATP4A | P20648 | 2/20 | 0.31 |
| ▸ | ATP4B | P51164 | 2/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801425 | 0.90 | BRD4 (0.36) | BRD4HTR6PTPN11SUV39H2 | |
| SCHEMBL1801618 | 0.86 | BRD4 (0.46) | BRD4ATP4AATP4BPTPN11SUV39H2 | |
| SCHEMBL12652263 | 0.85 | SUV39H2 (0.32) | SUV39H2 | |
| SCHEMBL1797528 | 0.84 | BRD4 (0.34) | BRD4CPT2CPT1ACPT1BHTR6 | |
| SCHEMBL1799532 | 0.82 | HTR2C (0.36) | BRD4PTPN11MEN1USP2HTT | |
| SCHEMBL1798773 | 0.82 | PDPK1 (0.36) | BRD4ATP4AATP4BPTPN11SUV39H2 | |
| SCHEMBL4555856 | 0.81 | BRD4 (0.36) | BRD4HTR6PTPN11SUV39H2 | |
| SCHEMBL1799966 | 0.80 | CPT1A (0.37) | BRD4CPT2CPT1ACPT1BHTR6 | |
| SCHEMBL2753133 | 0.79 | PDPK1 (0.42) | BRD4HTR6PTPN11SUV39H2 | |
| SCHEMBL1801394 | 0.79 | BRD4 (0.35) | BRD4HTR6PTPN11SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | BRD4 728/4885CPT2 3722/4885CPT1A 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.